Syros Pharmaceuticals (SYRS) Misses Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Syros Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Multiple Upcoming Clinical Milestones for Its First-in-Class Programs
March 7, 2019 7:30 AM ESTExpects to Report Updated Data on SY-1425 in Combination with Azacitidine in Newly Diagnosed Unfit AML Patients in Second Half of 2019
Expects to Report Initial Data from Expansion Portion of Phase 1 Trial of SY-1365 in Fourth Quarter of 2019
Announces Plans to Expand Ongoing Phase 2 Trial of SY-1425 in Combination with Azacitidine to Include Biomarker-Positive Relapsed or Refractory AML Patients
Announces New Expansion Cohort to Evaluate SY-1365 in Recurrent Ovarian Clear Cell Cancer Patients
Management to Host Conference Call at 8:30 a.m. ET... More
